 The incidence of BK virus, BKV, veremia and BKV associated nephropathy, BKVN, has increased significantly since the mid-1990s. It is believed that a more powerful immunosuppressive treatment may be responsible for this phenomenon. The use of tachrylimus, TAC, combined with mycophenolic acid, MPA, has gained momentum in the same period, which suggests that this combination may be the cause of the increased incidence of BKV. Additionally, mTOR inhibitors, mTORIs, have been shown to have antiviral properties in vitro, suggesting that they may be effective against BKV. However, the results are mixed, with some studies showing positive effects while others show no effect. Therefore, further research is needed to determine whether mTORIs can be used safely in conjunction with CNIs to reduce the risk of BKV infection. This article was authored by Thomas Jove, Lionel Rosting and Paolo Malvetsi. We are article.tv, links in the description below.